Solid Biosciences Inc. Insider Trading
SLDB
Insiders sold $2.68M and bought nothing on the open market.
All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Mar 2025.
Get an email when SLDB's executives or directors buy, or make a large sale outside a plan.
Trades · last 2 years
| Date | Insider | Trade | Shares | Price | Value | Of their stake | Filing |
|---|---|---|---|---|---|---|---|
| Oct 19 | Gabriel Brooks Chief Medical Officer | Sold10b5-1 plan | 4,374 | $5.62 | 25K | 4.3% | Form 4 |
| Feb 18 | Alexander Cumbo President and CEO | Sold10b5-1 plan | 16,644 | $5.82 | 97K | 6.6% | Form 4 |
| Feb 18 | Jessie Hanrahan Chief Regulatory Officer | Sold10b5-1 plan | 4,134 | $5.82 | 24K | 5.3% | Form 4 |
| Feb 18 | Ilan Ganot Director | Sold10b5-1 plan | 2,658 | $5.82 | 15K | 1.8% | Form 4 |
| Feb 18 | Paul Herzich Chief Technology Officer | Sold10b5-1 plan | 3,616 | $5.82 | 21K | 4.7% | Form 4 |
| Feb 18 | David T Howton Chief Operating Officer | Sold10b5-1 plan | 7,469 | $5.82 | 43K | 6.6% | Form 4 |
| Feb 18 | Gabriel Brooks Chief Medical Officer | Sold10b5-1 plan | 0 | — | $0 | — | Form 4 |
| Feb 18 | Kevin Tan CFO & Treasurer | Sold10b5-1 plan | 5,404 | $5.82 | 31K | 5.2% | Form 4 |
| Feb 4 | David T Howton Chief Operating Officer | Sold10b5-1 plan | 18,894 | $6.44 | 122K | 16% | Form 4 |
| Feb 4 | Alexander Cumbo President and CEO | Sold10b5-1 plan | 48,913 | $6.44 | 315K | 18% | Form 4 |
| Feb 4 | Ilan Ganot Director | Sold10b5-1 plan | 7,205 | $6.44 | 46K | 4.8% | Form 4 |
| Feb 4 | Kevin Tan CFO & Treasurer | Sold10b5-1 plan | 14,783 | $6.44 | 95K | 14% | Form 4 |
| Feb 4 | Gabriel Brooks Chief Medical Officer | Sold10b5-1 plan | 12,616 | $6.44 | 81K | 13% | Form 4 |
| Feb 4 | Jessie Hanrahan Chief Regulatory Officer | Sold10b5-1 plan | 12,348 | $6.44 | 80K | 15% | Form 4 |
| Feb 4 | Paul Herzich Chief Technology Officer | Sold10b5-1 plan | 10,905 | $6.44 | 70K | 14% | Form 4 |
| Feb 2 | Kevin Tan CFO & Treasurer | Sold10b5-1 plan | 26,837 | $6.44 | 173K | 20% | Form 4 |
| Feb 2 | Alexander Cumbo President and CEO | Sold10b5-1 plan | 80,258 | $6.44 | 517K | 23% | Form 4 |
| Feb 2 | Jessie Hanrahan Chief Regulatory Officer | Sold10b5-1 plan | 26,535 | $6.44 | 171K | 24% | Form 4 |
| Feb 2 | Gabriel Brooks Chief Medical Officer | Sold10b5-1 plan | 28,335 | $6.44 | 182K | 23% | Form 4 |
| Feb 2 | David T Howton Chief Operating Officer | Sold10b5-1 plan | 37,771 | $6.44 | 243K | 24% | Form 4 |
| Feb 2 | Paul Herzich Chief Technology Officer | Sold10b5-1 plan | 26,250 | $6.44 | 169K | 25% | Form 4 |
| Jan 28 | Ilan Ganot Director | Sold10b5-1 plan | 191 | $6.59 | 1K | 0.1% | Form 4 |
| Jan 13 | Kevin Tan CFO & Treasurer | Sold10b5-1 plan | 5,704 | $5.27 | 30K | 11% | Form 4 |
| Jan 5 | Ilan Ganot Director | SoldNo plan | 1,053 | $5.43 | 6K | 0.8% | Form 4 |
| Dec 3, 2025 | David T Howton Chief Operating Officer | Sold10b5-1 plan | 4,932 | $5.11 | 25K | 13% | Form 4 |
| Dec 3, 2025 | Alexander Cumbo President and CEO | Sold10b5-1 plan | 10,808 | $5.11 | 55K | 12% | Form 4 |
| Dec 3, 2025 | Jessie Hanrahan Chief Regulatory Officer | Sold10b5-1 plan | 4,483 | $5.11 | 23K | 14% | Form 4 |
| Dec 3, 2025 | Paul Herzich Chief Technology Officer | Sold10b5-1 plan | 2,701 | $5.11 | 14K | 9.2% | Form 4 |
| Nov 10, 2025 | Ilan Ganot Director | SoldNo plan | 3,278 | $4.12 | 14K | 2.5% | Form 4 |
| Oct 20, 2025 | Gabriel Brooks Chief Medical Officer | SoldNo plan | 2,895 | $5.96 | 17K | 7.9% | Form 4 |
| Mar 11, 2025 | Clare Kahn Director | Bought | 1,860 | $5.34 | 10K | 169% | Form 4 |
| Feb 19, 2025 | Joseph Edelman Director | Bought | 5,000,000 | $4.03 | $20.1M | 73% | Form 4 |
| Feb 19, 2025 | Bcls SB Investco, LP Large holder | Bought | 1,000,000 | $4.03 | $4.03M | 25% | Form 4 |
| Feb 18, 2025 | Robert Atchinson Large holder | Bought | 252,545 | $7.56 | $1.91M | 6.3% | Form 4 |
| Feb 14, 2025 | Jessie Hanrahan Chief Regulatory Officer | Sold10b5-1 plan | 3,079 | $3.96 | 12K | 14% | Form 4 |
| Feb 14, 2025 | Gabriel Brooks Chief Medical Officer | Sold10b5-1 plan | 3,256 | $3.96 | 13K | 12% | Form 4 |
| Feb 14, 2025 | Kevin Tan CFO & Treasurer | Sold10b5-1 plan | 3,164 | $3.96 | 13K | 8.9% | Form 4 |
| Feb 14, 2025 | Paul Herzich Chief Technology Officer | Sold10b5-1 plan | 2,688 | $3.96 | 11K | 13% | Form 4 |
| Feb 14, 2025 | Alexander Cumbo President and CEO | Sold10b5-1 plan | 11,365 | $3.96 | 45K | 16% | Form 4 |
| Feb 14, 2025 | Ilan Ganot Director | Sold10b5-1 plan | 1,711 | $3.96 | 7K | 1.3% | Form 4 |
- Oct 1910b5-1 planGabriel BrooksChief Medical Officer · sold 4,374 at $5.6225K4.3% of stake
- Feb 1810b5-1 planAlexander CumboPresident and CEO · sold 16,644 at $5.8297K6.6% of stake
- Feb 1810b5-1 planJessie HanrahanChief Regulatory Officer · sold 4,134 at $5.8224K5.3% of stake
- Feb 1810b5-1 planIlan GanotDirector · sold 2,658 at $5.8215K1.8% of stake
- Feb 1810b5-1 planPaul HerzichChief Technology Officer · sold 3,616 at $5.8221K4.7% of stake
- Feb 1810b5-1 planDavid T HowtonChief Operating Officer · sold 7,469 at $5.8243K6.6% of stake
- Feb 1810b5-1 planGabriel BrooksChief Medical Officer · sold 0$0— of stake
- Feb 1810b5-1 planKevin TanCFO & Treasurer · sold 5,404 at $5.8231K5.2% of stake
- Feb 410b5-1 planDavid T HowtonChief Operating Officer · sold 18,894 at $6.44122K16% of stake
- Feb 410b5-1 planAlexander CumboPresident and CEO · sold 48,913 at $6.44315K18% of stake
- Feb 410b5-1 planIlan GanotDirector · sold 7,205 at $6.4446K4.8% of stake
- Feb 410b5-1 planKevin TanCFO & Treasurer · sold 14,783 at $6.4495K14% of stake
- Feb 410b5-1 planGabriel BrooksChief Medical Officer · sold 12,616 at $6.4481K13% of stake
- Feb 410b5-1 planJessie HanrahanChief Regulatory Officer · sold 12,348 at $6.4480K15% of stake
- Feb 410b5-1 planPaul HerzichChief Technology Officer · sold 10,905 at $6.4470K14% of stake
- Feb 210b5-1 planKevin TanCFO & Treasurer · sold 26,837 at $6.44173K20% of stake
- Feb 210b5-1 planAlexander CumboPresident and CEO · sold 80,258 at $6.44517K23% of stake
- Feb 210b5-1 planJessie HanrahanChief Regulatory Officer · sold 26,535 at $6.44171K24% of stake
- Feb 210b5-1 planGabriel BrooksChief Medical Officer · sold 28,335 at $6.44182K23% of stake
- Feb 210b5-1 planDavid T HowtonChief Operating Officer · sold 37,771 at $6.44243K24% of stake
- Feb 210b5-1 planPaul HerzichChief Technology Officer · sold 26,250 at $6.44169K25% of stake
- Jan 2810b5-1 planIlan GanotDirector · sold 191 at $6.591K0.1% of stake
- Jan 1310b5-1 planKevin TanCFO & Treasurer · sold 5,704 at $5.2730K11% of stake
- Jan 5No planIlan GanotDirector · sold 1,053 at $5.436K0.8% of stake
- Dec 3, 202510b5-1 planDavid T HowtonChief Operating Officer · sold 4,932 at $5.1125K13% of stake
- Dec 3, 202510b5-1 planAlexander CumboPresident and CEO · sold 10,808 at $5.1155K12% of stake
- Dec 3, 202510b5-1 planJessie HanrahanChief Regulatory Officer · sold 4,483 at $5.1123K14% of stake
- Dec 3, 202510b5-1 planPaul HerzichChief Technology Officer · sold 2,701 at $5.1114K9.2% of stake
- Nov 10, 2025No planIlan GanotDirector · sold 3,278 at $4.1214K2.5% of stake
- Oct 20, 2025No planGabriel BrooksChief Medical Officer · sold 2,895 at $5.9617K7.9% of stake
- Mar 11, 2025Clare KahnDirector · bought 1,860 at $5.3410K169% of stake
- Feb 19, 2025Joseph EdelmanDirector · bought 5,000,000 at $4.03$20.1M73% of stake
- Feb 19, 2025Bcls SB Investco, LPLarge holder · bought 1,000,000 at $4.03$4.03M25% of stake
- Feb 18, 2025Robert AtchinsonLarge holder · bought 252,545 at $7.56$1.91M6.3% of stake
- Feb 14, 202510b5-1 planJessie HanrahanChief Regulatory Officer · sold 3,079 at $3.9612K14% of stake
- Feb 14, 202510b5-1 planGabriel BrooksChief Medical Officer · sold 3,256 at $3.9613K12% of stake
- Feb 14, 202510b5-1 planKevin TanCFO & Treasurer · sold 3,164 at $3.9613K8.9% of stake
- Feb 14, 202510b5-1 planPaul HerzichChief Technology Officer · sold 2,688 at $3.9611K13% of stake
- Feb 14, 202510b5-1 planAlexander CumboPresident and CEO · sold 11,365 at $3.9645K16% of stake
- Feb 14, 202510b5-1 planIlan GanotDirector · sold 1,711 at $3.967K1.3% of stake
Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with SLDB
Held by ETFs
SLDB is in 20 US ETFs. The largest of them, with SLDB's weight in each:
Spot a number that looks wrong? Check it in SLDB's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing SLDB
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.